Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2004

View Archived Issues

Numax enters new phase III RSV study in Native American infants

New U.S. site added to phase II ProCord study for acute spinal cord injury

Tetrodin studied in phase II trial of opiate-dependent subjects

Full enrollment achieved in phase III study of Celacade for PAD

Lorus signs Virulizin supply agreement with BioVectra

Crucell highlights progress

Doxorubicin Transdrug receives European orphan drug status

Fast track status for XP-12B for menorrhagia

Australian phase II study of Testosterone MDTS completed

Raven files IND for phase I study of RAV-12 in advanced adenocarcinoma

Nesterone MDTS contraceptive spray enters clinical testing

In vitro and in vivo characterization of SLV-326, a novel cannabinoid CB1 receptor antagonist

Aldosterone synthase inhibition with FAD-286: a novel therapy for the treatment of CHF

HS-2-45: a novel anticonvulsant reported to modulate Na+ channel gating

In vitro, in vivo characterization of JNJ-17308616, a novel anxiolytic V1a receptor antagonist

Scientists at AmorePacific claim genistein for the treatment of obesity

ARS investigators describe a new use of clusterin for peripheral neurological diseases

New use of ritonavir for unconjugated hyperbilirubinemia claimed by Abbott

Vertex patent covers protein kinase inhibitors

Protein kinase modulators claimed by Exelixis

GSK-3beta inhibitors for the treatment of neurodegenerative diseases

Antiatherosclerotic effects of oral apolipoprotein A-I mimetic

Phase II data on the immunogenicity of the influenza vaccine FluBlok in elderly subjects

Preclinical profile of WAY-909, a novel selective 5-HT2C receptor selective agonist

Rosuvastatin significantly improves hypercholesterolemia in African Americans

Pexelizumab reduces mortality in patients undergoing CABG and aortic valve surgery

Antiviral effects, pharmacokinetics and safety of VX-950 in HCV infection

Update on the antitumor effects and safety of lapatinib in advanced breast cancer

Safety, distribution of ChimeriVax-West Nile vaccine assessed in monkeys

Vaxfectin enhances antimalarial plasmid DNA vaccines

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.